NasdaqGS:JAZZPharmaceuticals
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story
Earlier this week, Jazz Pharmaceuticals reported practice-changing results from its HERIZON-GEA trial and outlined plans to submit a supplemental Biologics License Application in the first half of 2026 for first-line gastroesophageal adenocarcinoma treatment as both doublet and triplet therapy with priority review.
An important angle for investors is the expectation that these data could support broad first-line use and potential guideline inclusion across overlapping gastrointestinal cancer...